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Purpose: We investigated how serum low-density lipoprotein (LDL) level is relat-
ed to various isoforms of apolipoprotein (ApoE) polymorphism in association with 
obesity and metabolic syndrome. Materials and Methods: We gathered total 332 
sample of postmenopausal Korean women and analyzed ApoE isoforms, serum lip-
id level including LDL, blood pressure, fasting glucose, and anthropometry. The re-
lationship between ApoE isoforms and serum lipid level, metabolic syndrome, and 
obesity was investigated. Results: Six ApoE isoforms were found, ApoE2 [E2/2 
(n=1), E2/3 (n=54), E2/4 (n=14)], ApoE3 (E3/3, n=200), ApoE4 [E3/4 (n=55), and 
E4/4 (n=8)]. The prevalence of metabolic syndrome and obesity showed higher 
ApoE3 isoform than that of other isoforms. In additon, ApoE3 isoform was related 
to higher serum LDL and total cholesterol level than to ApoE2 isoform. The odds 
ratio of having the highest LDL cholesterol quartile in ApoE3 with obesity, com-
pared to ApoE2 without obesity, was 3.46 [95% confidence interval (CI); 1.07-
11.14, p=0.037], and odds ratio of ApoE3 with metabolic syndrome compared to 
ApoE2 without metabolic syndrome was 5.06 (95% CI; 1.14-22.29, p=0.037). Se-
rum LDL cholesterol was positively associated with obesity or metabolic syndrome 
in ApoE3 isoform. Conclusion: This study suggests that obesity or metabolic syn-
drome risk should be effectively managed in ApoE3 isomform groups to reduce se-
rum LDL in postmenopausal Korean women. 
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INTRODUCTION
Apolipoprotein E (ApoE) is a 34 kDa protein that plays an important role in lipo-
protein metabolism by association with lipoprotein particles and with members of 
the low-density lipoprotein (LDL) receptor family.1,2 It has been known that there 
are three apoE isoforms, E2, E3 and E4, have different affinities for their binding 
receptors. In case of apoE2, defective characteristics of binding to low density li-
poprotein receptor (LDLR) by cysteine at amino acid position 158,3 which affects 
up-regulation of synthesis of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-
CoA) and LDLR and finally results in low serum LDL level. Therefore, even Duck-Joo Lee, et al.
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three years, ApoE polymorphism, including LDL cholester-
ol, and anthropometry, we compared the presence of obesi-
ty, metabolic syndrome, and related metabolic parameters 
according to their ApoE polymorphism. To be consistent 
with previous publications,15 we defined three ApoE iso-
form groups: 1) the ApoE2 group included those subjects 
carrying the E2/E2 or E3/E2 or E4/E2 genotype; 2) the 
ApoE3 group included those carrying the E3/E3 genotype; 
and 3) the ApoE4 group included those carrying the E4/E3 
or E4/E4 genotype. Additionally, we evaluated the odds ra-
tios of having highest LDL-cholesterol among ApoE iso-
forms with or without obesity.
Measurements
Anthropometry and laboratory test
Height and body weight of the participants were measured 
while they were light clothing without shoes. Weight was 
measured to the nearest 0.1 kg, and height was measured 
to the nearest centimeter. Body mass index was calculated 
as the weight divided by height squared (BMI, kg/m2). 
Trained nurses measured the waist circumference between 
the lower rib and the iliac crest, and electrically measured 
blood pressure after the participants had been at rest for at 
least 15 minutes (TM-2655P; PMS Instruments, Higashi-
Ikebukuro, Toshima-Ku, Tokyo, Japan). Additionally, all 
of the subjects underwent blood test [standard enzymatic 
measurements of total cholesterol, high-density lipoprotein 
(HDL) cholesterol, triglycerides and fasting glucose in 
fresh serum samples (TBA-200FR, Toshiba, Tokyo, Ja-
pan)].
Genetic analysis of ApoE
Leukocyte DNA was derived from 5-10 mL of whole blood 
as previously described.16 ApoE genotyping was performed 
as described by Hixson and Vernier.17 A 244 bp sequence of 
the ApoE gene, including the two polymorphic sites, was 
amplified by PCR in a DNA Thermal Cycler (PTC-100; MJ 
Research, Watertown, MA, USA), using oligonucleotide 
primers F4 and F6. Each reaction mixture was heated at 
94°C for 2 minutes, followed by 35 cycles of amplification 
(94°C for 40 s, 62°C for 30 s, and 72°C for 1 min). The PCR 
products were digested with 5 units of HhaI, and the frag-
ments were separated by electrophoresis on an 8% polyacryl-
amide nondenaturing gel. After electrophoresis, the gel was 
treated with ethidium bromide for 30 min, and DNA frag-
ments were visualized by ultraviolet illumination. 
though those with the allele epsilon2 have a (low) risk for the 
rare form of hyperlipidemia (type III),4 they actually have rel-
atively low LDL-C. In contrast, E4 has a characteristic of 
rapid clearance and down-regulation of both HMA-CoA and 
LDLR, which causes the increase of plasma LDL level. 
There were some reports that dysregulated adipose tis-
sue, as seen in cases of obesity and lipoatrophy, raises the 
risk of morbidity from hypertension, dyslipidemia, type 2 
diabetes and cardiovascular disease.5,6 Recent research on 
cross-talk of adipose tissue with other organs by the adipo-
cytokines and other proteins, one of which is known for 
ApoE.7 Other articles on ApoE function of body fatness 
regulation were reported.8-10 Of those study, one large study 
known as The Atherosclerosis Risk in Communities (ARIC) 
Study has reported that the ApoE isoforms are associated 
with increasing body mass index in the order: ApoE2> 
ApoE3>ApoE4.9 Other epidemiologic study have repre-
sented that the presence of at least one ApoE4 allele is asso-
ciated with a greater risk of coronary artery disease.11,12 
Which increasing risk could be from elevated plasma LDL 
cholesterol, a well-established risk factor in the field of lip-
id-lowering treatment.13,14
There is no previous report on the ApoE polymorphism 
related to the LDL cholesterol and other metabolic parame-
ters in the postmenopausal Korean women. Therefore, we 
investigated how serum LDL level is related to various iso-
forms of ApoE polymorphism in association with obesity 
and metabolic syndrome. 
MATERIALS AND METHODS
Study subjects and design
Three hundreds thirty two postmenopausal Korean women 
were enrolled, whose data came from their routine health 
check-up after informed consent for this study to evaluate 
the ApoE polymorphism and metabolic abnormalities in the 
Health Promotion Center, Ajou University Hospital, Su-
won, South Korea, from 2002 to 2004. The socioeconomic 
status of the subjects was relatively high, because most of 
the subjects were housewives of the executives in one big, 
well-known company in Korea. They all gave the informed 
consent, and Institutional Review Board of Ajou University 
Hospital approved this study. 
Study design
Using the data of study subjects which were gathered for ApoE Polymorphism and LDL Cholesterol
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terol, LDL cholesterol, triglyceride, and fasting blood sugar, 
showed normal ranges. ApoE is composed of six geno-
types, E2/2, E2/3, E2/4, E3/3, E3/4, and E4/4, therefore, we 
simply grouped them into three groups by following previ-
ous publications; E2 (E2/2, E2/3, E2/4), E3 (E3/3), E4 (E3/4, 
E4/4). Proportions of each genotypes were 20.8% (n=69), 
60.2% (n=200), and 19% (n=63), respectively. ApoE3/3 iso-
form had higher prevalence of metabolic syndrome and 
obesity than other ApoE isoforms (Fig. 1). In addition, the 
comparisons between ApoE isoforms and metabolic pa-
The definition of obesity and metabolic syndrome in this study
Obesity was defined as BMI≥25 kg/m2, using body weight 
and height in all subjects, according to the Asian guideline, 
and central obesity was also defined as waist circumference 
≥90 cm for men and ≥85 cm for women, defined in 2006 by 
Korean Society of Study of Obesity.18 We followed NCEP-
ATP III Asian guideline19 components to define metabolic 
syndrome, which are consisted of central obesity (waist cir-
cumference≥90 cm for men and ≥85 cm for women), blood 
pressure≥130/80 mmHg, triglyceride≥150 mg/dL, fasting 
glucose≥110 mg/dL, and low high-density lipoprotein cho-
lesterol (men<40 mg/dL, women<50 mg/dL). In that guide-
line, subjects who have more than 3 abnormal values men-
tioned above were defined as metabolic syndrome subjects. 
Statistics
Chi-square tests to compare proportions across all ApoE iso-
forms (E2, E3, E4) and metabolic syndrome, obesity groups, 
and ANOVA test to compare means of continuous variables 
such as various metabolic parameters across all groups were 
used. Analysis of covariance was used to determine the LDL 
level among ApoE groups, adjusting for covariates such as 
age, BMI, blood pressure, HDL, logTG, fasting blood sugar, 
daily activity and regular exercise. Multivariate logistic anal-
ysis was done to evaluate the odds ratio of having highest 
quartile of LDL cholesterol. 
RESULTS
  
Table 1 shows baseline characteristics of all study subjects. 
Their mean age was 61.8 years, and they were all post-
menopausal Korean women. Mean BMI was 23.7, indicat-
ing that overall body weight of subjects was overweight. 
Mean values of metabolic parameters, including waist cir-
cumference, blood pressure, total cholesterol, HDL choles-
Table 1. Baseline Characteristics of Study Subjects
Variables Women (n=332)
Age (yrs)   61.8±5.9
Height (cm)  155.9±5.2
Body weight (kg)   57.8±7.1
BMI (kg/m
2)   23.7±2.7
Wc (cm)   76.5±6.4
s-BP (mmHg)   128.2±16.5
d-BP (mmHg)     78.3±10.3
TC (mg/dL)   198.4±35.3
HDLC (mg/dL)     54.3±15.2
LDLC (mg/dL)   104.3±48.4
TG (mg/dL)   126.6±77.9
FBS (mg/dL)     108.4±110.2
E2 (n=69) E2/E2 (%)   1 (0.3)
E2/E3 (%)   54 (16.3)
E2/E4 (%) 14 (4.2)
E3 (n=200) E3/E3 (%) 200 (60.2)
E4 (n=63) E3/E4 (%)   55 (16.6)
E4/E4 (%)   8 (2.4)
Hypertension     23 (6.9%)
Diabetes  20 (6%)
All values are mean±stadard deviation. BMI is calculated from body 
weight (kg)/height (m
2). E2; including E2/E2, E2/E3, E2/E4. E3; including 
E3/E3. E4; including E3/E4, E4/E4.
Wc, waist circumference; s-BP, systolic blood pressure; d-BP, diastolic 
blood pressure; TC, total cholesterol; HDLC, high-density lipoprotein cho-
lesterol; LDLC, low-density lipoprotein cholesterol; TG, triglyceride; FBS, 
fasting blood sugar.
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Fig. 1. The prevalence of metabolic syndrome and obesity according to the ApoE isoforms. This figure represents the prevalence of metabolic syndrome and 
obesity according to the ApoE isoforms. ApoE3/3 isoform showed higher prevalence of metabolic syndrome and obesity than other ApoE isoforms (p<0.05). 
MS, metabolic syndrome; OB, obesity.Duck-Joo Lee, et al.
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DISCUSSION
In our cross-sectional study, we found that postmenopausal 
Korean women had various ApoE isoforms, however, over 
half of subjects had ApoE3 (E3/3, 60.2%) isoform, which 
was similar to previous studies. In metabolic concern, ApoE3 
isoform showed higher LDL cholesterol than ApoE2 (E2/2, 
E2/E3, E2/E4) isoform. In addition, the odds ratio of having 
the highest LDL cholesterol quartile in each ApoE isoform 
with or without obesity or metabolic syndrome was 3.46 in 
ApoE3 isoform with obesity, and  5.06 with metabolic syn-
drome compared to ApoE2 without obesity or metabolic syn-
drome, respectively, showing significant difference. 
Previous studies showed that increased risk of CHD as-
sociated with having small, dense LDL particles might be 
modulated to a significant extent by the presence/absence 
of insulin resistance, abdominal obesity and increased LDL 
particle concentration,20 and that the risk attributable to 
small LDL particles might partly be independent of the 
concomitant variation in plasma lipoprotein-lipid concen-
rameters showed that the difference in total cholesterol and 
LDL cholesterol, between the groups was also significant af-
ter adjustment of age, BMI, blood pressure, HDL, LogTG, 
fasting blood sugar, and daily physical activity (Table 2). 
ApoE3 isoform showed significantly higher LDL cholester-
ol and total cholesterol than ApoE2 isoform (Fig. 2). ApeE4 
isoform was not significantly different in the level of LDL-
C compared to the other types of ApoE. 
We divided LDL cholesterol by quartiles and compared 
the odds ratios of having the highest LDL cholesterol quartile 
among ApoE isoforms with or without obesity and metabolic 
syndrome. We set ApoE2 isoform without obesity or meta-
bolic syndrome as reference group. ApoE3 isoform with obe-
sity (OR=3.46, 95% CI; 1.07-11.14, p=0.037) or metabolic 
syndrome (OR=5.06, 95% CI; 1.14-22.29, p=0.037) showed 
significantly higher odds ratio of having the highest quartile 
of LDL cholesterol, compared to ApoE2 isoform without 
obesity or metabolic syndrome, after age adjustment. Addi-
tionally, the odds ratio of ApoE4 isoform was not significant 
compared to the ApoE3 isoform, even though the odds ratios 
were higher than those of the ApoE3 isoform (Table 3).
Table 2. Comparisons of Metabolic Parameters According to the ApoE Isoforms
Variables E2 (n=69) E3 (n=200) E4 (n=63) p value
Ages (yrs) 62.2 (5.6) 61.9 (6.0) 61.0 (6.1) 0.442
Wc (cm) 74.4 (4.3) 75.6 (3.5) 75.2 (3.5) 0.775
s-BP (mmHg) 129.0 (17.3) 127.8 (16.9) 128.4 (14.3) 0.885
d-BP (mmHg)   78.7 (10.6)   78.1 (10.7) 78.7 (9.1) 0.890
TC (mg/dL) 184.8 (33.6) 202.5 (34.0) 199.6 (38.2)   0.002*
HDL (mg/dL)   55.8 (15.4)   54.3 (15.1)   52.4 (15.7) 0.470
LDL (mg/dL)   85.6 (47.2) 109.7 (46.0) 106.8 (53.0)   0.002*
Log TG (mg/dL)   2.02 (0.23)   2.05 (0.21)   2.08 (0.24) 0.396
FBS (mg/dL)   99.5 (16.7)   112.6 (139.9) 104.7 (29.6) 0.690
All values are mean (standard deviation). E2; including E2/E2, E2/E3, E2/E4. E3; including E3/E3. E4; including E3/E4, E4/E4.
Wc, waist circumference; s-BP, systolic blood pressure; d-BP, diastolic blood pressure; TC, total cholesterol; HDL, high-density lipopro-
tein; LDL, low-density lipoprotein; Log TG, log-transformed TG.
All p values are from ANOVA test before adjustment.
*p<0.05 using ANCOVA test after adjustment including age, BMI, s-BP, d-BP, HDL, Log TG, FBS, and daily physical activity.
Fig. 2. The relationship between ApoE isoforms, LDL-cholesterol, and Total cholesterol level. This figure represents LDL-cholesterol 
(above) and Total cholesterol level according to the ApoE isoforms. E2 type has low LDL-cholesterol and total cholesterol level compared 
to the E3 type. E2; including E2/E2, E2/E3, E2/E4, E3; including E3/E3.
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search is needed to evaluate the relationship between the 
cardiovascular event or mortality and ApoE polymorphism, 
especially ApoE2, E3, E4. In case of ApoE4, the odds ratio 
of having the highest quartile of LDL-cholesterol was high-
er than those of ApoE3, but there was no significance in 
statistical aspect. That result might have been due to rela-
tively small frequency of ApoE4 compared to the ApoE331 
or there in no component on LDL-cholesterol in defining 
the metabolic syndrome. Further study is needed to find out 
that result. 
There are several limitations in this study. We analyzed 
the data of postmenopausal Korean women, which may 
have critical selection bias to interpret the various LDL cho-
lesterol level and obesity. And not all subjects were not obese 
(29.1%) and there were no results on men. Most of subjects 
were high economic status group. In addition, we didn’t 
carry out full adjustment to evaluate the difference of each 
ApoE isoforms such as smoking (most of subjects were 
non-smokers), alcohol consumption, exercise time, sleep 
time and so on. 
In conclusion, ApoE3 isoform among ApoE polymor-
phism was significantly correlated with higher serum LDL 
than other ApoE isofoms. Serum LDL cholesterol was pos-
itively associated with obesity or metabolic syndrome in 
ApoE3 isoform. This study suggests that obesity or meta-
bolic syndrome risk should effectively be managed in post-
menopausal Korean women with ApoE3 isomform to re-
duce serum LDL. 
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